Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 4Breast Neoplasms 3Parkinson Disease 4, Autosomal Dominant Lewy Body 2Esophageal Neoplasms 2Urinary Bladder Neoplasms 1Ureteral Neoplasms 1Ovarian Neoplasms 1Metastatic Hormone-sensitive Prostate Cancer 1Metastatic Castration Resistant Prostate Cancer 1Fallopian Tube Neoplasms 1Carcinoma, Ovarian Epithelial 1

Interventions

enfortumab vedotin 4pembrolizumab 2Gemcitabine 2Cisplatin 2vinflunine 1ulixertinib 1trastuzumab biosimilar HLX02 1trametinib 1sapanisertib 1sacituzumab govitecan 1relatlimab 1pertuzumab 1palbociclib 1osimertinib 1omipalisib 1larotrectinib 1ipatasertib 1erdafitinib 1durvalumab 1defactinib 1dabrafenib 1copanlisib 1capivasertib 1binimetinib 1avelumab 1adavosertib 1X-Rays 1Trastuzumab 1Surgical Procedures, Operative 1Sunitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has announcements × Urinary Bladder Neoplasms × Docetaxel × Clear all
NCT03474107 2026-01-09

A Study to Evaluate Enfortumab Vedotin Versus (vs) Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301)

Astellas Pharma Inc

Phase 3 Completed
608 enrolled 22 charts 1 FDA
Genitourinary

Urinary Bladder Neoplasms, Ureteral Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡